Phaseline

Targets › SNAP25

SNAP25 (Synaptosomal-associated protein 25): drug programs, companies and trials

15 programs from 14 companies in 63 trials: 22 Phase 2, 19 Phase 4, 17 Phase 3, 5 Phase 1; Other, Neurology, Immunology; next expected readout Nov 2026.

t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. (UniProt, P60880)

Open in Phaseline: the race on SNAP25, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johns Hopkins UniversityAbobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 4Adolescent Idiopathic ScoliosisDec 2026
Universidade Federal FluminenseAbobotulinumtoxinA
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 4Spastic ParaplegiaFeb 2027
Montefiore Medical CenterDaxibotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 4Benign Essential BlepharospasmMar 2027
AbbVieOnabotulinumtoxinA
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 4Jawline and Neck Appearance; Urinary Bladder, Overactive; Overactive Bladder; Trigeminal Neuralgia …Jun 2027
IpsenBotulinum Toxin Type A
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
SNAP25Phase 3Chronic Migraine; Episodic Migraine; Obstructed Defaecation Syndrome; Rhizarthrosis …Nov 2026
Merz TherapeuticsIncobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 3Chronic Migraine; Episodic Migraine; Fissure in Ano; Stroke …Mar 2027
Merz PharmaceuticalsIncobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 3Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain InjuryApr 2027
Huons BiopharmaHU-045
Botulinum toxin type A; cleaves SNAP25 to block acetylcholine release at the neuromuscular
SNAP25Phase 3Glabellar LinesMay 2027
Merz AestheticsIncobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 3Neuromuscular AgentsAug 2027
Merz North AmericaIncobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 3Neuromuscular AgentsSep 2027
Henry Ford Health SystemAbobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 2ScarDec 2026
AbbVieTrenibotulinumtoxine (AGN-151586)
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
SNAP25Phase 2Forehead Lines; Upper Facial Lines; Glabellar LinesFeb 2027
All India Institute of Medical SciencesBotulinum Toxin Type A Injection [Botox]
Botulinum toxin A injection into cricopharyngeus muscle to reduce muscle hypertonia and im
SNAP25Phase 2Transfer DysphagiaAug 2027
University of PennsylvaniaDaxibotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 2Blepharospasm of Both EyelidsJun 2028
BiojivaBotulinum Toxin Type A (RT001)
Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
SNAP25Phase 2Infantile Neuroaxonal Dystrophy–

Conditions

Chronic Migraine (3) Overactive Bladder (3) Episodic Migraine (2) Stroke (2) Glabellar Lines (2) Neuromuscular Agents (2) Infantile Neuroaxonal Dystrophy (1) Fissure in Ano (1) Focal Hand Dystonia (1) Peripheral Neuropathy Due to Chemotherapy (1) Androgenetic Alopecia (1) Provoked Vestibulodynia (1)

Modalities

protein or peptide (11), small molecule (3), mixed (1)

Companies

AbbVie (2) Biojiva (1) Merz Therapeutics (1) Ipsen (1) All India Institute of Medical Sciences (1) Montefiore Medical Center (1) Huons Biopharma (1) Universidade Federal Fluminense (1) Johns Hopkins University (1) Merz Aesthetics (1) University of Pennsylvania (1) Merz Pharmaceuticals (1) Merz North America (1) Henry Ford Health System (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.